BiotechTube
ProBio

ProBio

1548
San Diego, United States· Est.
probiocdmo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

ProBio, a subsidiary of GenScript Biotech (HKEX: 1548), is a global CDMO with a mission of 'Innovation through Collaboration' to accelerate biologics and CGT development. Its strategic advantage lies in integrated, proprietary technology platforms (e.g., ProSpeed™, ExpressCMC™, PowerS™ strains) and a proven track record of supporting over 150 IND approvals globally since 2017. The company operates a worldwide network of facilities, including a flagship CGT center in New Jersey, positioning it as a one-stop partner for biotechs from discovery to commercialization.

BiologicsCell Therapy

Technology Platform

ProBio's edge is built on proprietary platforms for speed and integration: ProSpeed™ for single B cell antibody discovery, ExpressCMC™ for rapid biologics CMC (as fast as 3.5 months), and the PowerS™ suite of bacterial strains for high-yield, high-quality plasmid DNA manufacturing for cell and gene therapies.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The massive growth in cell & gene therapy and mRNA/LNP therapeutics drives unprecedented demand for specialized CDMO capacity.
ProBio's new flagship GMP center in New Jersey positions it to capture high-value U.S.
clients, while its full-service, platform-driven approach allows it to benefit from the entire wave of biologics innovation.

Risk Factors

Key risks include geopolitical tensions affecting its U.S.-China operational model, intense price competition in the crowded CDMO market, and execution risks associated with rapidly scaling its advanced therapy manufacturing capacity and technology platforms.

Competitive Landscape

ProBio competes with large, diversified CDMOs like Lonza and WuXi Biologics, and pure-play CGT specialists. Its differentiation lies in deep integration with parent GenScript's gene synthesis expertise, a strong portfolio of proprietary tech platforms (ProSpeed, PowerS), and a proven track record of over 150 global IND approvals.

More companies in Biologics / Biosimilars →More companies in United States →